General News

Single dose of AstraZeneca vaccine drastically cuts COVID-19 transmission: UK study

Britain’s well being chief says a brand new study exhibiting {that a} single dose of the COVID-19 vaccine developed by Oxford College and AstraZeneca gives a excessive degree of safety for 12 weeks helps the federal government’s technique of delaying the second shot so extra doses may be delivered to extra folks.

Well being Secretary Matt Hancock’s feedback got here after Oxford launched a study exhibiting the vaccine lower transmission of the virus by two-thirds and prevented extreme illness. The study has not been peer-reviewed but, nevertheless it was greeted with pleasure by U.Okay. officers beneath stress to justify their resolution to delay the second dose.

“That discount in transmission, in addition to the very fact there isn’t any hospitalizations, the mixture of that is superb information. And it categorically helps the technique we’ve been taking over having a 12-week hole between the doses,” Hancock advised Sky Information on Wednesday.

Pharmacist Bhaveen Patel administers a dose of the Oxford/AstraZeneca covid vaccine to Joshua Labor at a coronavirus vaccination clinic held at Junction Pharmacy in Brixton, London, Thursday, Jan. 28, 2021.
Pharmacist Bhaveen Patel administers a dose of the Oxford/AstraZeneca covid vaccine to Joshua Labor at a coronavirus vaccination clinic held at Junction Pharmacy in Brixton, London, Thursday, Jan. 28, 2021.
AP

One of the lead researchers on the venture, Dr. Andrew Pollard of Oxford College, stated Oxford scientists consider the vaccine will proceed to supply safety in opposition to new variants of COVID-19, though they’re nonetheless ready for knowledge on this.

Even when the virus adapts, “that doesn’t imply that we received’t nonetheless have safety in opposition to extreme illness.’’

“If we do have to replace the vaccines, then it’s truly a comparatively easy course of it solely takes a matter of months, quite than the massive efforts that everybody went via final 12 months to get the very large-scale trials run,” he advised the BBC.

About the author

Donna Miller

Donna is one of the oldest contributors of Gruntstuff and she has a unique perspective with regards to Science which makes her write news from the Science field. She aims to empower the readers with the delivery of apt factual analysis of various news pieces from Science. Donna has 3.5 years of experience in news-based content creation, and she is now an expert at it. She loves journalism, and that is the reason, she moved from a web content writer to a News writer, and she is loving it. She is a fun-loving woman who has very good connections with every team member. She makes the working environment cheerful which improves the team’s work productivity.

Add Comment

Click here to post a comment

Get in Touch!

To get in touch with gruntstuff or to tell us about a Story or Press Release, just send an email to gruntstuffnews @ gmail.com
. And, we will get back to you shortly.